• Ave. 31 No. 15802 between 158 y 190, Cubanacán, Playa, Havana. C.P. 11600, P.O. Box 6162
  • webmaster@cigb.edu.cu
  • (53) 7-2504101; (53) 7-2716022
Mambisa, anti-COVID-19 vaccine candidate About Mambisa Abdala: the first COVID-19 vaccine in Latin America About Abdala Abdala is 100% effective in preventing severe illness and death from COVID-19 About Abdala We research, produce and commercialize biotechnological and pharmaceutical products About us We work with social responsibility and in harmony with the environment About us We offer innovative biotechnological applications for the biomedical, veterinary, agricultural, aquaculture and industrial sectors About us Agricultural biotechnology with its own technology and varieties of Cuban plants Plant products Food sustainability and sovereignty ¿Quiénes somos? We work for one health About us We seek answers, we offer solutions About us About Abdala About Abdala

Message from the Director General

“We have been able to motivate young people to become what we have become. We had the opportunity to work with a very committed generation, and we have a duty to follow that example.”

Our studies focus on

Research areas

that generate a positive impact on human, animal and plant health, as well as industrial productions, in harmony with the environment, to contribute to the socioeconomic development of Cuba

Our directives


First vaccine against COVID-19 in Latin America.


Phase III clinical study of Abdala

Efficacy against symptomatic disease
Efficacy in preventing severe systemic disease and death of vaccinated people
Effectiveness in critically ill patients
Upcoming events

Where you can know our results

We work for one health

We offer + 25 products

Our products are preventive, therapeutic or diagnostic. We design products first and only of its kind for diseases that have no other effective therapeutic solutions.

What do we work on?

Main processes